UCB Japan (headquarters: Shinjuku-ku, Tokyo; president: Kanako Kikuchi; hereafter referred to as “UCB Japan”; when referring to the global UCB group, “UCB”) and Astellas Pharma Inc. (headquarters: Chuo-ku, Tokyo; president and CEO: Kenji Yasukawa , Ph.D. hereafter referred to as “Astellas”) announced today that companies have newly launched Cimzia® (certolizumab pegol) 200mg AutoClicks® for S.C. Injection in Japan as an additional formulation to the PEGylated*1 TNF-alpha (tumor necrosis factor-alpha) inhibitor Cimzia® 200mg Syringe for S.C. Injection for the treatment of rheumatoid arthritis (RA).
UCB is committed to providing value to patients and meeting their unique needs. As part of this commitment, UCB continued its partnership with OXO, a company known for thoughtful, consumer friendly designs, to develop the AutoClicks® Prefilled Pen, based on core technology licensed from Bespak. The AutoClicks® Prefilled Pen provides a button-free delivery system and a wide non-slip grip that keeps patient hand disability in mind. It has a large viewing window that shows the progress of the injection and it makes a clicking noise at the start of the injection and again when the injection is complete, giving patients confidence to know they have received their full dose of Cimzia®.
UCB Japan and Astellas believe that the AutoClicks® Prefilled Pen will be able to provide RA patients and medical professionals with a new treatment option and contribute further to treatment of the disease.